SREBF1 and colonic neoplasm: Torres-Ayuso et al. (26) explored the potential molecular mechanism of DGKZ's role in rapamycin-resistant colon cancer cell line, and found that DGKZ manipulated mTORC1 and lipogenic metabolism in colon cancer cells through SREBP-1.